Skip to main content
Premium Trial:

Request an Annual Quote

Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker

Premium

Sirnaomics said last week that it has signed a deal with Chinese drug company Guangdong Zhongsheng Pharmaceutical to develop siRNA-based therapeutics for diabetic retinopathy and age-related macular degeneration.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

Guangdong Zhongsheng has agreed to pay Sirnaomics up to $9.75 million in upfront and milestone payments under the deal, as well as royalties and market-territory sharing considerations.

Additional terms were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.